UBS Group
PCRX icon

UBS Group’s Pacira BioSciences PCRX Stock Holding History

UBS Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$18K – 9211
2014
Q4 		$18K Buy
+200
New +$18.9K ﹤0.01% 7801

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's PCRX Position: Q1 2026 in Review

UBS Group increased its Pacira BioSciences (PCRX) stake by 0.61% in Q1 2026, buying an estimated $75.3K and bringing the position to 562,040 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3092.

UBS Group first reported a position in PCRX in Q4 2014 and has held it in 46 quarters since. The position peaked at $25.9M in Q4 2024. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • UBS Group held 562,040 shares of Pacira BioSciences worth $12.7M as of Q1 2026.
  • UBS Group bought 3,389 Pacira BioSciences shares in Q1 2026, an estimated $75.3K.
  • Pacira BioSciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3092 holding.
  • UBS Group first reported a position in Pacira BioSciences in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Pacira BioSciences position peaked at $25.9M in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.